We at Synovo are happy to announce our latest publication in Inflammopharmacology and with it our new class of Fumarate Esters. This class of highly active MMF derivatives are part of our macrolide based compounds and is intended to be used as an anti-inflammatory drug in autoimmune diseases (e.g. psoriasis). We were able to propose two possible mode of actions. One more important in cell-based assays and depended on a Michael addition to glutathion (or other thiol groups) and a second one based on the agonistic binding of MMF to the G protein-coupled receptor GPR109A.